Pharmaceutical composition for oral administration of a GLP-1 receptor agonist

A pH-buffered pharmaceutical composition using phosphate, citrate, and bicarbonate buffers protects GLP-1 receptor agonists from digestive enzymes, enabling effective oral delivery by maintaining biological activity.

FR3120189B1Active Publication Date: 2024-11-29BENNIS FARID
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
FR2021001947
Authority / Receiving Office
FR · FR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-03-01
Publication Date
2024-11-29
Estimated Expiration
2041-03-01

AI Technical Summary

Technical Problem

Existing GLP-1 receptor agonists are susceptible to rapid degradation by digestive enzymes in the stomach and intestine, limiting their effective oral administration due to the lack of adequate protection in current formulations.

Method used

A pharmaceutical composition comprising a GLP-1 receptor agonist and a buffering system that maintains a pH range of 4 to 8, using buffers like phosphate, citrate, and bicarbonate to protect the agonist from degradation by enzymes such as pepsin and trypsin.

Benefits of technology

The composition effectively protects at least 70% of the GLP-1 receptor agonist from degradation, ensuring its biological activity is retained throughout the digestive tract, thereby facilitating oral administration.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Pharmaceutical composition for oral administration of a GLP-1 receptor agonist. The invention relates to a pharmaceutical composition for use as a drug, in the oral treatment of a disease, in particular a metabolic disease, said pharmaceutical composition comprising a Glucagon-like peptide-1 (GLP-1) receptor agonist, and a system capable of buffering the pharmaceutical composition to a pH ranging from 4 to 8.
Need to check novelty before this filing date? Find Prior Art

Description

Title of the invention: Pharmaceutical composition for oral administration of a GLP-1 receptor agonist Technical field

[0001] The invention relates to a pharmaceutical composition for use as a medicament, in the oral treatment of a disease, said pharmaceutical composition comprising (i) a proteinaceous active ingredient, said proteinaceous active ingredient being a Glucagon-like peptide-1 (GLP-1) receptor agonist, and (ii) a system capable of buffering the pharmaceutical composition at a pH ranging from 4 to 8. Prior art

[0002] Glucagon-like peptide-1 or GLP-1 is an incretin, i.e. an intestinal hormone secreted by endocrine intestinal cells in response to food intake. GLP-1 modulates carbohydrate homeostasis by binding to the GLP-1 receptor, specific to pancreatic beta cells. The main biological effects of GLP-1 receptor activation are stimulation of glucose-dependent insulin secretion, inhibition of postprandial glucagon secretion (called glucose-dependent action), slowing of gastric emptying, and inhibition of gastric acid secretion (called satietogenic action). The biologically active forms of GLP-1, i.e. GLP-1 (7-36) and GLP-1 (7-37), are obtained after proteolytic cleavage of the initial product GLP-1 (1-37).

[0003] GLP-1 has a strong therapeutic interest in the regulation of hyperglycemia and in the treatment of type 2 diabetes. However, the active forms of GLP-1, i.e. GLP-1 (7-36) and GLP-1 (7-37), have a very short lifespan due to rapid inactivation by the serum enzyme DPP-4 (dipeptidyl peptidase 4).

[0004] To overcome the constraints linked to this inactivation of GLP-1 by DPP-4, two classes of GLP-1 receptor agonists have been developed as drugs: GLP-1 analogues and exendin 4 analogues (Exenatide). However, these GLP-1 receptor agonists remain sensitive to degradation by digestive enzymes, such as pepsin in the stomach and trypsin in the intestine, which presents a disadvantage for their oral administration.

[0005] GLP-1 receptor agonists are therefore administered parenterally. The product Ozempic® is a drug in injectable form comprising semaglutide. The product Byetta® is also a drug in injectable form and comprising exenatide. However, this route of administration is technically restrictive and less comfortable for the patient than the oral route, particularly when administered daily. Administration by the parenteral route re-entry also poses compliance problems for patients.

[0006] Formulations for oral administration of GLP-1 receptor agonists described in the literature generally comprise a compound capable of protecting the GLP-1 receptor agonist from degradation by digestive enzymes. This is the case, for example, of the formulation described in document US 2011 / 0046053, which is an oral or rectal composition for administering exenatide with a trypsin inhibitor, EDTA and fish oil. The composition comprises a coating which makes it possible to inhibit digestion by the stomach and therefore to protect the protein active ingredient from degradation.Other documents describe the incorporation of a GLP-1 receptor agonist into a polymeric particle (WO 2020 / 028907), or the use of minerals such as copper, iron, or zinc in association with an absorption activator, in order to inhibit proteases and thus avoid degradation by digestive enzymes (WO 2017 / 060500).

[0007] Document WO 2012 / 080471 describes the use as a medicament for oral administration of a solid composition comprising a GLP-1 receptor agonist and a carrier agent called SNAC (or sait of N-(8-(2hydroxybenzoyl)amino)caprylic acid). The SNAC compound makes it possible to protect the GLP-1 receptor agonist by inhibiting digestive enzymes during passage through the stomach and to improve its absorption. The product Rybelsus® comprises in particular semaglutide, in combination with a SNAC compound and is indicated for oral administration.

[0008] However, there remains a need to develop new compositions suitable for oral administration of a GLP-1 receptor agonist which can guarantee optimal protection of the agonist throughout the digestive tract, in particular against digestive enzymes such as pepsin. Summary of the invention

[0009] Thus, the present invention, which finds application in the pharmaceutical field, aims to propose a pharmaceutical composition which makes it possible to protect GLP-1 receptor agonists against degradation by digestive enzymes.

[0010] According to a first aspect, the invention relates to a pharmaceutical composition for use as a medicament, in the oral treatment of a disease, said pharmaceutical composition comprising (i) a proteinaceous active ingredient, said proteinaceous active ingredient being a Glucagon-like peptide-1 (GLP-1) receptor agonist, and (ii) a system capable of buffering the pharmaceutical composition at a pH ranging from 4 to 8.

[0011] According to a second aspect, the invention relates to a process for preparing a composition according to the invention, in which a protein active ingredient is mixed with a system capable of buffering the pharmaceutical composition at a pH ranging from 4 to 8, said protein active being a GLP-1 receptor agonist.

[0012] According to a third aspect, the invention relates to a kit of reagents, also called kit-of-parts, for use as a medicament, in the oral treatment of a disease, said kit of reagents comprising: (i) a pharmaceutical composition in solid form comprising a protein active ingredient, said protein active ingredient being a Glucagon-like peptide-1 (GLP-1) receptor agonist, and (ii) a pharmaceutical composition comprising a buffer system, wherein said pharmaceutical composition comprising a buffer system (ii) is capable of buffering the pharmaceutical composition comprising the protein active ingredient (i) at a pH ranging from 4 to 8, when compositions (i) and (ii) are mixed in solution. Detailed description

[0013] Definitions

[0014] The term "pharmaceutical composition" means a composition suitable for pharmaceutical use. The pharmaceutical composition may comprise one or more pharmaceutically acceptable excipients.

[0015] The term "pharmaceutically acceptable excipient" means diluents, adjuvants or vehicles, such as preservatives, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersants, lubricants, antibacterial and antifungal agents, isotonic agents, absorption retardants and their analogues. It is understood that none of these pharmaceutically acceptable excipients is capable of protecting the protein active ingredient from degradation by digestive enzymes in the pharmaceutical composition according to the invention.

[0016] The term "oral treatment" is understood to mean administration via the gastrointestinal tract.

[0017] The term “protein active ingredient” designates an active ingredient consisting of a chain of amino acid residues linked together by peptide bonds, such as a protein or a peptide.

[0018] The term "GLP-1 receptor agonist" refers to a proteinaceous active ingredient that partially or fully activates the GLP-1 receptor. The GLP-1 receptor agonist may bind to the GLP-1 receptor, with an affinity constant (Kd) of less than 1pM, e.g., 100 nM, and measured using conventional methods, e.g., described in WO 98 / 08871. Methods for identifying a GLP-1 receptor agonist may comprise (i) contacting the GLP-1 receptor with a candidate GLP-1 receptor agonist, and (ii) measuring a detectable change in one or more of the biological activities associated with GLP-1 receptor activation. A GLP-1 receptor agonist may be selected among GLP-1, a GLP-1 analog, exendin-4 (also known as "Exenatide") and / or an exendin-4 analog. Preferably, a GLP-1 receptor agonist is (a) GLP-1 or a GLP-1 analog selected from liraglutide, dulaglutide, albiglutide and semaglutide, preferably semaglutide, or (b) exendin-4 or an exendin-4 analog, selected from exenatide and lixisenatide.

[0019] The term "GLP-1" corresponds to the GLP-1 (1-37) form, the GLP-1 (7-37) form or the GLP-1 (7-36) form. It may be GLP-1 of human or animal origin, for example GLP-1 of amino acid sequence SEQ ID NO: 1 which corresponds to the (1-37) form of human GLP-1, GLP-1 of amino acid sequence SEQ ID NO: 2 which corresponds to the (7-36) form of human GLP-1, or GLP-1 of amino acid sequence SEQ ID NO: 3 which corresponds to the (7-37) form of human GLP-1.

[0020] A "GLP-1 analog" means a GLP-1 whose amino acid sequence has one or more amino acids substituted by another amino acid and / or one or more amino acids deleted and / or one or more amino acids added. Generally, the GLP-1 analog has at least 90% sequence homology with the corresponding GLP-1. The GLP-1 analog may also comprise one or more amino acids modified, for example by acylation, alkylation, reduction, oxidation or crosslinking. The GLP-1 analog may also be fused to a molecule for increasing the half-life of said GLP-1 analog, for example an Fc fragment of an immunoglobulin G, albumin, a fatty acid and / or polyethylene glycol (PEG). The GLP-1 analogue may be chosen from liraglutide, dulaglutide, albiglutide and semaglutide, preferably semaglutide.

[0021] Liraglutide corresponds to the (7-37) form of human GLP-1 in which arginine 34 is substituted by a lysine and in which position 26 is modified with a C16 fatty acid.

[0022] Dulaglutide corresponds to the (7-37) form of human GLP-1 fused to an Fc fragment of IgG4.

[0023] Albiglutide results from the fusion of a dimer of (7-36) forms of human GLP-1 with a human albumin. The two (7-36) forms of human GLP-1 of the dimer each have a glycine in place of alanine at position 2.

[0024] Semaglutide corresponds to the (7-37) form of human GLP-1 whose positions 8 and 34 have been mutated.

[0025] The term "exendin-4" refers to a 39-amino acid protein found in the salivary glands of a giant lizard, the "Gila monster." Exenatide is the recombinant or synthetic form of exendin-4. Exenatide is resistant to DPP4 activity.

[0026] The term "exendin-4 analog" refers to an exendin-4 whose sequence in amino acids has one or more amino acids substituted by another amino acid and / or one or more amino acids deleted and / or one or more amino acids added. An exendin-4 analog may also comprise one or more amino acids modified, for example by acylation, alkylation, reduction, oxidation or crosslinking. The exendin-4 analog may also be fused to a molecule for increasing the half-life of said exendin-4 analog, for example an Fc fragment of an immunoglobulin G, albumin, a fatty acid and / or polyethylene glycol (PEG). The exendin-4 analog may for example be lixisenatide. Lixisenatide comprises 44 amino acids and corresponds to exendin-4 with proline 38 missing and 6 lysine residues added.

[0027] The expression "system capable of buffering the pharmaceutical composition" in the context of the invention designates a system capable of exerting a buffering effect on the pharmaceutical composition, in particular in the gastric environment and in the intestinal environment.

[0028] The expression "additional compound capable of protecting the protein active ingredient against degradation by digestive enzymes" designates a compound, other than the system capable of buffering the pharmaceutical composition, capable of protecting the protein active ingredient against degradation by digestive enzymes, of preventing the degradation of the protein active ingredient by digestive enzymes present in the gastric juice and / or the pancreatic juice during the digestion process such as proteases, preferably chosen from pepsin, trypsin or chymotrypsin, in particular pepsin.

[0029] The present invention arises from the surprising advantages demonstrated by the inventors of the effect of a system capable of buffering a pharmaceutical composition on the protection of a GLP-1 receptor agonist against degradation by digestive enzymes.

[0030] Pharmaceutical composition

[0031] According to a first aspect, the invention relates to a pharmaceutical composition for use as a medicament, in the oral treatment of a disease, said pharmaceutical composition comprising (i) a protein active ingredient, said protein active ingredient being a Glucagon-like peptide-1 (GLP-1) receptor agonist, and (ii) a system capable of buffering the pharmaceutical composition at a pH ranging from 4 to 8. The disease may be a metabolic disease such as type 2 diabetes, non-alcoholic steatohepatitis (NASH) and / or obesity. Preferably, the disease is type 2 diabetes. In particular in the context of the treatment of obesity, the composition according to the invention makes it possible to reduce appetite, to induce satiety, which results in a reduction in food intake.

[0032] The system capable of buffering the pharmaceutical composition makes it possible to obtain a pharmaceutical composition at a pH ranging from 4 to 8, for example at a pH ranging from 4.5 to 7.5, at a pH ranging from 5 to 7, at a pH ranging from 5.5 to 7, at a pH ranging from 6 to 7. In a particularly preferred manner, the system capable of buffering the pharmaceutical composition makes it possible to obtain a pharmaceutical composition at a pH ranging from 6.5 to 7.

[0033] This system is capable of protecting the protein active ingredient against degradation by digestive enzymes, such as proteases, preferably chosen from pepsin, trypsin or chymotrypsin, in particular pepsin. In the context of the invention, the protection by the system capable of buffering the pharmaceutical composition corresponds to an inactivation of the effect of the digestive enzymes in the gastrointestinal environment.

[0034] The protection of the protein active ingredient can be measured by a structural analysis of the active ingredient, for example by HPLC. The protection of the protein active ingredient can also be measured by a functional analysis of the active ingredient, for example by measuring the biological activity of the protein active ingredient. The biological activity of the protein active ingredient can be easily determined by looking at its effect on the GLP-1 receptor, for example by implementing a functional test, such as a measurement of the agonist effect on the GLP-1 receptor. The measurement of the agonist effect on the GLP-1 receptor can for example be carried out on hamster kidney cells by measuring the production of cyclic AMP.

[0035] In the examples of the present application, the protection of the protein active ingredient is measured by HPLC.

[0036] The amount of protein active ingredient present in the composition according to the invention, namely the GLP-1 receptor agonist, may be adjusted by the person skilled in the art of the disease to be treated. The pharmaceutical composition according to the invention may comprise from 0.0001 to 5% by mass of the GLP-1 receptor agonist relative to the total mass of the pharmaceutical composition, preferably from 0.001 to 1% by mass of the GLP-1 receptor agonist, more preferably from 0.01 to 0.5%, for example 0.08%, 0.2% or 0.4%. For example, the pharmaceutical composition according to the invention comprises 0.08%, 0.2% or 0.4% by mass of semaglutide relative to the total mass of the pharmaceutical composition.

[0037] Advantageously, the system is capable of protecting at least 70% of the protein active ingredient (by structural or functional analysis) from degradation by at least one digestive enzyme when the pharmaceutical composition is brought into contact with said digestive enzyme(s), for example at least 75%, at least 80%, at least 85%, at least 90%, at least 95%. 100% protection of the protein active ingredient corresponds to a protein active ingredient that has not undergone any degradation. gradation and having retained all of its biological activity. A 70% protection of the protein active ingredient corresponds to an active ingredient degraded to 30%, that is to say that, in a composition comprising the protein active ingredient, 70% of the protein active ingredient is not degraded and 30% of the protein active ingredient is degraded. A 0% protection of the protein active ingredient corresponds to an active ingredient that is totally degraded and has lost all of its biological activity. Advantageously, the system is capable of protecting at least 70%, at least 80%, at least 90% of the protein active ingredient from degradation by pepsin, for example when the pharmaceutical composition is brought into contact with 2 to 5 mg / mL of pepsin, for example 3.2 mg / mL of pepsin, for one hour or for two hours.

[0038] The system capable of buffering the pharmaceutical composition may be chosen from the list of buffer systems given in the European Pharmacopoeia, current edition (monograph 4.1.3). Preferably, the system capable of buffering the pharmaceutical composition according to the invention is chosen from the following buffers: phosphate, acetate, maleate, phthalate, succinate, citrate, such as anhydrous monosodium citrate, imidazole, tetrabutylammonium, trihydroxymethylaminomethane, tris-glycine, bicarbonate such as sodium bicarbonate, barbitol, tris-EDTA BSA, copper sulfate and zwitterionic. The system capable of buffering the pharmaceutical composition advantageously comprises a phosphate buffer, such as monosodium phosphate dihydrate, a citrate buffer, such as anhydrous monosodium citrate, and a bicarbonate buffer, such as sodium bicarbonate.In a particular embodiment, the system capable of buffering the pharmaceutical composition consists of a phosphate buffer, such as monosodium phosphate dihydrate, a citrate buffer, such as anhydrous monosodium citrate, and a bicarbonate buffer, such as sodium bicarbonate.

[0039] The pharmaceutical composition according to the invention may comprise from 5 to 99% by mass of system capable of buffering the composition relative to the total mass of the pharmaceutical composition, preferably from 10 to 80%, in particular from 20 to 50%, for example 30%, 35%, 40%, 45%, 55%, 60%, 65%, 70%, 75%, 80% by mass of system capable of buffering the composition relative to the total mass of the pharmaceutical composition. In another embodiment of the invention, the pharmaceutical composition according to the invention may comprise from 50 to 99% by mass of system capable of buffering the composition relative to the total mass of the pharmaceutical composition, preferably from 70 to 99%, in particular from 80 to 99%, for example 85%, 90%, 95% 98% by mass of system capable of buffering the composition relative to the total mass of the pharmaceutical composition.

[0040] In a particular embodiment, the system capable of buffering the com- pharmaceutical position includes: (i) from 0.5 to 20% by mass of mono-sodium phosphate dihydrate relative to the total mass of the system capable of buffering the pharmaceutical composition, preferably from 1 to 15%, more preferably from 2 to 10% by mass of mono-sodium phosphate dihydrate relative to the total mass of the system capable of buffering the pharmaceutical composition, (ii) from 10 to 60% by mass of anhydrous monosodium citrate relative to the total mass of the system capable of buffering the pharmaceutical composition, preferably from 20 to 50%, more preferably from 30 to 45% by mass of anhydrous monosodium citrate relative to the total mass of the system capable of buffering the pharmaceutical composition, and (iii) from 20 to 95% by mass of sodium bicarbonate relative to the total mass of the system capable of buffering the pharmaceutical composition, preferably from 40 to 80%, more preferably from 50 to 70% by mass of sodium bicarbonate relative to the total mass of the system capable of buffering the pharmaceutical composition.

[0041] In a very particular embodiment, the system capable of buffering the pharmaceutical composition comprises: (i) about 5% by mass of mono-sodium phosphate dihydrate relative to the total mass of the system capable of buffering the pharmaceutical composition, (ii) about 35% by mass of anhydrous monosodium citrate relative to the total mass of the system capable of buffering the composition, and (iii) about 60% by mass of sodium bicarbonate relative to the total mass of the system capable of buffering the pharmaceutical composition.

[0042] According to a preferred embodiment, the pharmaceutical composition is free of any additional compound capable of protecting the protein active ingredient against degradation by digestive enzymes. In this embodiment, the system capable of buffering the pharmaceutical composition at a pH ranging from 4 to 8 is therefore the only compound present in the pharmaceutical composition having the capacity to protect the protein active ingredient against degradation by digestive enzymes. In particular, the pharmaceutical composition according to the invention does not comprise a physical protection system such as a coating, a coating, a matrix, a capsule wall, such as a liposome enveloping the protein active ingredient and protecting it from degradation by digestive enzymes.In particular, the pharmaceutical composition according to the invention is free from a compound capable of inhibiting the action of digestive enzymes, such as for example a mineral, a SNAC compound, pepstatin, a diazoketone, an alginate and / or a soy extract.

[0043] Preferably, the composition according to the invention does not comprise any other(s) protein active ingredient(s), such as insulin, one of its derivatives or one of its analogues.

[0044] The composition may be in solid or liquid form.

[0045] When the composition is in solid form, it comprises a system capable of buffering the pharmaceutical composition when it is dissolved, for example in the stomach after taking the pharmaceutical composition according to the invention orally. A solid composition may be, for example, in the form of tablets, in particular dispersible, orodispersible, effervescent tablets, capsules, a powder, an effervescent powder, granules, effervescent granules or a lyophilisate. Preferably, the composition is in an effervescent form, advantageously in the form of effervescent tablets.

[0046] In a particular embodiment and when the composition is in solid form, the system capable of buffering the pharmaceutical composition comprises: (i) from 0.5 to 20% by mass of mono-sodium phosphate dihydrate relative to the total mass of the pharmaceutical composition, preferably from 1 to 15%, more preferably from 2 to 10% by mass of mono-sodium phosphate dihydrate relative to the total mass of the pharmaceutical composition, (ii) from 10 to 60% by mass of anhydrous monosodium citrate relative to the total mass of the pharmaceutical composition, preferably from 20 to 50%, more preferably from 30 to 45% by mass of anhydrous monosodium citrate relative to the total mass of the pharmaceutical composition, and (iii) from 20 to 95% by mass of sodium bicarbonate relative to the total mass of the system capable of buffering the pharmaceutical composition, preferably from 40 to 80%, more preferably from 50 to 70% by mass of sodium bicarbonate relative to the total mass of the pharmaceutical composition.

[0047] In a very particular embodiment and when the composition is in solid form, the system capable of buffering the pharmaceutical composition comprises: (i) approximately 3.5% by mass of monosodium phosphate dihydrate relative to the total mass of the pharmaceutical composition, (ii) about 32% by mass of anhydrous monosodium citrate relative to the total mass of the pharmaceutical composition, and (iii) approximately 59% by mass of sodium bicarbonate relative to the total mass of the pharmaceutical composition.

[0048] In a very preferred embodiment of the invention and when the composition is in solid form, the pharmaceutical composition according to the invention comprises: (i) from 0.5 to 20% by mass of mono-sodium phosphate dihydrate relative to the total mass of the pharmaceutical composition, preferably from 1 to 15%, more preferably from 2 to 10% by mass of mono-sodium phosphate dihydrate per relative to the total mass of the pharmaceutical composition, for example 3.5%, (ii) from 10 to 60% by mass of anhydrous monosodium citrate relative to the total mass of the pharmaceutical composition, preferably from 20 to 50%, more preferably from 30 to 45% by mass of anhydrous monosodium citrate relative to the total mass of the pharmaceutical composition, for example 32%, (iii) from 20 to 95% by mass of sodium bicarbonate relative to the total mass of the system capable of buffering the pharmaceutical composition, preferably from 40 to 80%, more preferably from 50 to 70% by mass of sodium bicarbonate relative to the total mass of the pharmaceutical composition, for example 59%, (iv) from 0.5 to 20% by mass of sodium benzoate relative to the total mass of the pharmaceutical composition, preferably from 1 to 10%, more preferably from 2 to 5% by mass of sodium benzoate relative to the total mass of the pharmaceutical composition, for example 4.5%, and (v) from 0.0001 to 5% by mass of the GLP-1 receptor agonist, preferably semaglutide, relative to the total mass of the pharmaceutical composition, preferably from 0.001 to 1%, more preferably from 0.01 to 0.5% by mass of the GLP-1 receptor agonist relative to the total mass of the pharmaceutical composition, for example 0.08%, 0.2% or 0.4%.

[0049] In a preferred embodiment of the invention and when the composition is in solid form, for example in the form of an effervescent tablet, the pharmaceutical composition according to the invention comprises: (i) 120 milligrams (mg) of monosodium phosphate dihydrate, (ii) 1142 mg of anhydrous monosodium citrate, (iii) 2076 mg of sodium bicarbonate, (iv) 157 mg of sodium benzoate relative to the total mass of the pharmaceutical composition, and (v) from 0.5 to 40 mg, preferably 3, 7 or 14 mg of a GLP-1 receptor agonist, preferably semaglutide.

[0050] Since the pharmaceutical composition may be free of additional compound capable of protecting the protein active ingredient against degradation by digestive enzymes, when the pharmaceutical composition according to the invention is in solid form, it does not have a gastro-resistant coating.

[0051] When the composition is in liquid form, it may be in the form of a solute, a suspension or a syrup.

[0052] The pharmaceutical composition may comprise one or more pharmaceutically acceptable excipients, which are suitable for the form of the composition chosen.

[0053] The composition according to the invention may separately comprise a protein active ingredient and a system capable of buffering the pharmaceutical composition. In this embodiment, the protein active ingredient and the system capable of buffering the pharmaceutical composition are administered jointly so that the composition according to the invention is buffered at the time of passage of the protein active ingredient into the digestive system.

[0054] In a particular embodiment, the composition for use according to the invention is prepared from (i) a system capable of buffering the pharmaceutical composition in the form of an effervescent tablet and (ii) a protein active ingredient in the form of a tablet, for example an effervescent tablet. The two tablets are then mixed in solution to form the composition for use according to the invention.

[0055] According to another embodiment, the composition according to the invention can be formulated in unit form, namely the protein active ingredient and the system capable of buffering the pharmaceutical composition are formulated together. Method

[0056] According to a second subject, the invention relates to a process for preparing a pharmaceutical composition according to the invention, in which a protein active ingredient is mixed with a system capable of buffering said pharmaceutical composition at a pH ranging from 4 to 8, said protein active ingredient being an agonist of the GLP-1 receptor Glucagon-like peptide-1 (GLP-1).

[0057] The preparation of such a composition is carried out according to the conventional methods described in the literature. A particular method of preparing a pharmaceutical composition according to the invention is detailed in the examples.

[0058] The preparation of a pharmaceutical composition in solid or liquid form is carried out using conventional methods described in the literature.

[0059] The preparation of a composition in solid form comprises the mixing of a protein active ingredient chosen from GLP-1 receptor agonists and a system capable of buffering said pharmaceutical composition at a pH ranging from 4 to 8. The buffer system will then be capable of buffering the composition in solid form when it is dissolved, for example in the stomach after taking the pharmaceutical composition according to the invention orally.

[0060] The characteristics of the pharmaceutical composition as described above, in particular in the “pharmaceutical composition” part, are applicable to the method according to the invention. Reagent kit (or Kit-of-parts)

[0061] According to a third object, the invention relates to a kit of reagents, also called kit-of-parts, for use as a medicament, in the oral treatment of a disease, said kit of reagents comprising: (i) a pharmaceutical composition in solid form comprising an active ingredient protein, said protein active ingredient being a Glucagon-like peptide-1 (GLP-1) receptor agonist, and (ii) a pharmaceutical composition comprising a buffer system, wherein said pharmaceutical composition comprising a buffer system (ii) is capable of buffering the pharmaceutical composition comprising the protein active ingredient (i) at a pH ranging from 4 to 8, when compositions (i) and (ii) are mixed in solution.

[0062] The disease may be a metabolic disease such as type 2 diabetes, non-alcoholic steatohepatitis (NASH) and / or obesity. Preferably, the disease is type 2 diabetes. In particular in the context of the treatment of obesity, the kit of reagents (or kit-of-parts) according to the invention makes it possible to reduce appetite, to induce satiety, which results in a reduction in food intake.

[0063] In the context of the reagent kit according to the invention, the pharmaceutical composition comprising a buffer system (ii) is capable of buffering the pharmaceutical composition comprising the protein active ingredient (i) at a pH ranging from 4 to 8, when the compositions (i) and (ii) are mixed in solution, for example at a pH ranging from 4.5 to 7.5, at a pH ranging from 5 to 7, at a pH ranging from 5.5 to 7, at a pH ranging from 6 to 7. In a particularly preferred manner, the pharmaceutical composition comprising a buffer system (ii) is capable of buffering the pharmaceutical composition comprising the protein active ingredient (i) at a pH ranging from 6.5 to 7, when the compositions (i) and (ii) are mixed in solution.

[0064] The buffer system of the pharmaceutical composition (ii) of the reagent kit, when mixed in solution with the pharmaceutical composition (i), is capable of protecting the protein active ingredient of the pharmaceutical composition (i) against degradation by digestive enzymes, such as proteases, preferably chosen from pepsin, trypsin or chymotrypsin, in particular pepsin. In the context of the invention, the protection by the buffer system of the pharmaceutical composition (ii) corresponds to an inactivation of the effect of the digestive enzymes in the gastrointestinal environment on the protein active ingredient of the pharmaceutical composition (i).

[0065] Once compositions (i) and (ii) of the reagent kit are mixed in solution, the protection of the protein active ingredient can be measured in the same way as for the pharmaceutical composition according to the invention, for example by HPLC.

[0066] Compositions (i) and (ii) of the reagent kit may be mixed in solution in the stomach after oral administration of pharmaceutical compositions (i) and (ii) separately. Alternatively, compositions (i) and (ii) may be mixed in solution prior to oral administration.

[0067] Advantageously, the buffer system of the pharmaceutical composition (ii), when mixed in solution with the pharmaceutical composition (i), is capable of protecting at least 70% of the protein active ingredient of the pharmaceutical composition (i) (by structural or functional analysis) from degradation by at least one digestive enzyme when the solution comprising the compositions (i) and (ii) is brought into contact with said digestive enzyme(s), for example at least 75%, at least 80%, at least 85%, at least 90%, at least 95%. A 100% protection of the protein active ingredient corresponds to a protein active ingredient which has not undergone any degradation and which has retained all of its biological activity.A 70% protection of the protein active ingredient corresponds to an active ingredient degraded to 30%, that is to say that, in a pharmaceutical composition (ii) comprising the protein active ingredient, 70% of the protein active ingredient is not degraded and 30% of the protein active ingredient is degraded. A 0% protection of the protein active ingredient corresponds to an active ingredient that is totally degraded and has lost all its biological activity. Advantageously, the buffer system is capable of protecting at least 70%, at least 80%, at least 90% of the protein active ingredient from degradation by pepsin, for example when the solution comprising compositions (i) and (ii) is brought into contact with 2 to 5 mg / mL of pepsin, for example 3.2 mg / mL of pepsin, for one hour or for two hours.

[0068] When the pharmaceutical composition (i) of the reagent kit is in solid form, it may be, for example, in the form of tablets, in particular dispersible, orodispersible, effervescent tablets, capsules, a powder, an effervescent powder, granules, effervescent granules or a lyophilisate, advantageously in the form of effervescent tablets.

[0069] When the pharmaceutical composition (i) of the reagent kit is in solid form, it may comprise from 0.5 to 40 mg of GLP-1 receptor agonist, preferably 3, 7 or 14 mg of a GLP-1 receptor agonist. For example, the pharmaceutical composition (i) comprises 3, 7 or 14 mg of semaglutide.

[0070] The pharmaceutical composition (i) of the reagent kit may comprise one or more pharmaceutically acceptable excipients, which are suitable for the solid form.

[0071] An example of a pharmaceutical composition (i) which can be used in the context of the reagent kit according to the invention corresponds to the commercial product Rybelsus®.

[0072] The buffer system of the pharmaceutical composition (ii) of the reagent kit may be chosen from the list of buffer systems given in the European Pharmacopoeia, current edition (monograph 4.1.3). Preferably, the buffer system of the pharmaceutical composition (ii) is chosen from the following buffers: phosphate, acetate, maleate, phthalate, succinate, citrate, such as anhydrous monosodium citrate, imidazole, tetrabutylammonium, trihydroxymethylaminomethane, tris-glycine, bicarbonate such as sodium bicarbonate, barbitol, tris-EDTA BSA, copper sulfate and zwitterionic acid. The buffer system of pharmaceutical composition (ii) advantageously comprises a phosphate buffer, such as monosodium phosphate dihydrate, a citrate buffer, such as anhydrous monosodium citrate, and a bicarbonate buffer, such as sodium bicarbonate. In a particular embodiment, the buffer system of pharmaceutical composition (ii) consists of a phosphate buffer, such as monosodium phosphate dihydrate, a citrate buffer, such as anhydrous monosodium citrate, and a bicarbonate buffer, such as sodium bicarbonate.

[0073] In a particular embodiment, the buffer system of the pharmaceutical composition (ii) of the reagent kit comprises: (i) from 0.5 to 20% by mass of mono-sodium phosphate dihydrate relative to the total mass of the buffer system of the pharmaceutical composition (ii), preferably from 1 to 15%, more preferably from 2 to 10% by mass of mono-sodium phosphate dihydrate relative to the total mass of the buffer system of the pharmaceutical composition (ii), (ii) from 10 to 60% by mass of anhydrous monosodium citrate relative to the total mass of the buffer system of the pharmaceutical composition (ii), preferably from 20 to 50%, more preferably from 30 to 45% by mass of anhydrous monosodium citrate relative to the total mass of the buffer system of the pharmaceutical composition (ii), and (iii) from 20 to 95% by mass of sodium bicarbonate relative to the total mass of the buffer system of the pharmaceutical composition (ii), preferably from 40 to 80%, more preferably from 50 to 70% by mass of sodium bicarbonate relative to the total mass of the buffer system of the pharmaceutical composition (ii).

[0074] In a very particular embodiment, the buffer system of the pharmaceutical composition (ii) comprises: (i) about 5% by mass of mono-sodium phosphate dihydrate relative to the total mass of the buffer system of the pharmaceutical composition (ii), (ii) about 35% by mass of anhydrous monosodium citrate relative to the total mass of the buffer system of the pharmaceutical composition (ii), and (iii) about 60% by mass of sodium bicarbonate relative to the total mass of the buffer system of the pharmaceutical composition (ii).

[0075] The pharmaceutical composition (ii) of the reagent kit may be in solid or liquid form.

[0076] When the pharmaceutical composition (ii) of the reagent kit is in the form solid, it may be for example in the form of tablets, in particular dispersible, orodispersible, effervescent, capsules, a powder, an effervescent powder, granules, effervescent granules or a lyophilisate. Preferably, the pharmaceutical composition (ii) is in an effervescent form, advantageously in the form of effervescent tablets.

[0077] When the pharmaceutical composition (ii) of the reagent kit is in solid form, for example in the form of an effervescent tablet, it preferably comprises: (i) 120 milligrams (mg) of monosodium phosphate dihydrate, (ii) 1142 mg of anhydrous monosodium citrate, (iii) 2076 mg of sodium bicarbonate, and (iv) 157 mg of sodium benzoate.

[0078] When the pharmaceutical composition (ii) of the reagent kit is in liquid form, it may be in the form of a solute, a suspension or a syrup.

[0079] The pharmaceutical composition (ii) of the reagent kit may comprise one or more pharmaceutically acceptable excipients, which are suitable for the form of the composition (ii) chosen.

[0080] Preferably the pharmaceutical composition (i) and the pharmaceutical composition (ii) are in solid form, for example in the form of effervescent tablets.

[0081] According to a preferred embodiment, the kit of reagents (or kit-of-parts) according to the invention is free of additional compound capable of protecting the protein active ingredient of the pharmaceutical composition (i) against degradation by digestive enzymes. In particular, the composition (i) and the composition (ii) are free of additional compound capable of protecting the protein active ingredient of the pharmaceutical composition (i) against degradation by digestive enzymes. In this embodiment, the buffer system of the pharmaceutical composition (ii) is the only compound present in the kit of reagents according to the invention having the capacity to protect the protein active ingredient of the pharmaceutical composition (i) against degradation by digestive enzymes.In particular, the pharmaceutical composition (i) comprising a protein active ingredient and the pharmaceutical composition (ii) comprising a buffer system do not comprise a physical protection system such as a coating, a coating, a matrix, a capsule wall, such as a liposome enveloping the protein active ingredient and protecting it from degradation by digestive enzymes. In particular, the pharmaceutical composition (i) comprising a protein active ingredient and the pharmaceutical composition (ii) comprising a buffer system are free from a compound capable of inhibiting the action of digestive enzymes, such as for example a mineral, a SNAC compound, pepstatin, a diazoketone, an alginate and / or a soy extract.

[0082] Preferably, the pharmaceutical composition (i) of the reagent kit comprising a protein active ingredient and the pharmaceutical composition (ii) comprising a buffer system do not comprise any other protein active ingredient(s), such as insulin, one of its derivatives or one of its analogues.

[0083] Since the pharmaceutical compositions (i) and (ii) of the reagent kit may be free of additional compound capable of protecting the protein active ingredient against degradation by digestive enzymes, when one or other of the pharmaceutical compositions (i) and (ii) are in solid form, they do not have a gastro-resistant coating.

[0084] Example

[0085] Example 1: Preparation of a system capable of buffering a pharmaceutical composition according to the invention.

[0086] Example IA:

[0087] A preparation in the form of effervescent tablets comprising a buffer system was prepared according to Table 1.

[0088] Step 1) Sodium hydrogen carbonate, anhydrous monosodium citrate, and monosodium phosphate dihydrate were dry mixed.

[0089] Step 2) The mixture obtained in step 1) was granulated using a wetting solution composed of water and 96% ethanol.

[0090] Step 3) The granules thus obtained were calibrated and then dried until a predetermined residual humidity was obtained.

[0091] Step 4) The granules were mixed with sodium benzoate.

[0092] Step 5) The final mixture was compressed to obtain hardness, resistance to the rupture, a predetermined diameter and mass.

[0093] The GLP-1 receptor agonist may be formulated separately and then mixed extemporaneously with the tablet once the tablet is dissolved or incorporated directly into the tablet as detailed in Example 1B. The tablet may thus be incorporated with a GLP-1 receptor agonist of its choice.

[0094] Table 1 shows the composition of the effervescent tablets thus prepared.

[0095] [Tables 1] Ingredients Quantity in mg / tablet Sodium hydrogen carbonate (also called sodium bicarbonate) 2076.0 Monosodium citrate anhydrous 1142.0 Sodium benzoate 157.2 Monosodium phosphate dihydrate 120.0 Ethanol 96% (evaporated during the drying step) QS granulation Purified water (evaporated during the drying step) QS granulation Total 3495.6 (i.e. 3.5 g)

[0096] Example IB:

[0097] A preparation in the form of effervescent tablets comprising a buffer system was prepared according to Table 2.

[0098] Step 1) Sodium hydrogen carbonate, anhydrous monosodium citrate, and monosodium phosphate dihydrate were dry mixed.

[0099] Step 2) The mixture obtained in step 1) was granulated using a wetting solution composed of water and 96% ethanol.

[0100] Step 3) The granules thus obtained were calibrated and then dried until a predetermined residual humidity was obtained.

[0101] Step 4) The granules were mixed with a semaglutide content of 3 mg, 7 mg or 14 mg relative to the total mass of the tablet and sodium benzoate.

[0102] Step 5) The final mixture was compressed to obtain tablets having a predetermined hardness, breaking strength, diameter and mass.

[0103] Table 2 shows the composition of the effervescent tablets thus prepared.

[0104] [Tables2] Ingredients Quantity in mg / tablet Sodium hydrogen carbonate (also called sodium bicarbonate) 2076.0 Monosodium citrate anhydrous 1142.0 Sodium benzoate 157.2 Monosodium phosphate dihydrate 120.0 Semaglutide 3.0 to 14.0 Ethanol 96% (evaporated during the drying step) QS granulation Purified water (evaporated during the drying step) QS granulation Total 3495.6 (i.e. 3.5 g)

[0105] Example 2: Measurement of the protection of semaglutide with a composition according to the invention, under gastric conditions reproduced in vitro (acid pH and addition of pepsin).

[0106] The objective of this test is to demonstrate the gastric stability of semaglutide in a composition according to the invention.

[0107] Step 1) The tablet obtained in Example IA was dissolved in 50 mL of drinking water to obtain a buffered solution.

[0108] Step 2) The simulated gastric medium was prepared with hydrochloric acid (0.2 N HCl), adjusting the pH to 1.2.

[0109] Step 3) The buffered solution obtained in step 1) was mixed with 50 ml of simulated gastric medium, in order to obtain a final solution of 100 ml with 0.1 N HCL.

[0110] Step 4) Semaglutide was added to the solution obtained in step 3), in order to obtain a final semaglutide concentration of 0.05 mg / ml.

[0111] Step 5) Pepsin was added to the solution obtained in step 4) at a final concentration of 3.2 mg / ml or without the addition of pepsin (pepsin-free), and the resulting solution was kept under constant stirring at 37°C for 2 hours.

[0112] The semaglutide assay was performed by ultra-high performance liquid chromatography (UHPLC) coupled to an ultraviolet (UV) detector using an external standard calibration. The residual semaglutide content was calculated by measuring the semaglutide content at time t relative to the initial semaglutide content. The result is a ratio expressed as a percentage (%). The residual semaglutide content corresponds to the percentage of protection of semaglutide.

[0113] [Tables 3] Residual semaglutide content (%) Simulated gastric medium at pH 1.2 (without pepsin) Simulated gastric medium at pH 1.2 with pepsin (3.2 mg / ml) Solution comprising semaglutide and without buffer system T Oh 100% T 2h 100% T Oh 0% T 2h 0%

[0114] [T ables 4] Residual semaglutide content (%) Simulated gastric medium at pH 1.2 (without pepsin) Simulated gastric medium at pH 1.2 with pepsin (3.2 mg / ml) Solution comprising semaglutide and buffered solution T Oh 103.5% T 2h 104.1% T Oh 104.6% T 2h 105.2%

[0115] Results

[0116] The results described in Tables 3 and 4 show that semaglutide was not protected in an acidic medium in the presence of pepsin when it was not formulated in a composition according to the invention (0% residual content with pepsin and without buffer system). When semaglutide was formulated with a buffer system according to the invention, semaglutide was not degraded after 2 hours with and without pepsin.

[0117] These results show that the composition according to the invention provides total protection of semaglutide against degradation by pepsin in a simulated gastric environment.

[0118] Example 3: Measurement of the protection of exenatide with a composition according to the invention, under gastric conditions reproduced in vitro (acid pH and addition of pepsin)

[0119] Step 1) An effervescent tablet (according to Example IA) was dissolved in 50 mL of drinking water to obtain a buffered solution.

[0120] Step 2) The simulated gastric medium was prepared with hydrochloric acid (0.2 N HCl), adjusting the pH to 1.2.

[0121] Step 3) The buffered solution obtained in step 1) was mixed with 50 ml of simulated gastric medium, in order to obtain a final solution of 100 ml with 0.1 HCL.

[0122] Step 4) Exenatide was then added to the solution obtained in step 3) to obtain a final concentration of 0.05 mg / mL (5 mg of exenatide in 100 mL final) or 1 mg / mL (5 mg of exenatide in 5 mL final) in the final solution. The solution was mixed to solubilize the exenatide and homogenize the solution.

[0123] Step 5) Pepsin was then added to the solution at the conventional dose of 3.2 mg / mL or without the addition of pepsin (pepsin-free). The solution was kept under constant stirring at 37°C for 2 hours.

[0124] The exenatide content was specifically measured by high-performance liquid chromatography (HPLC). The residual content was calculated by measuring the exenatide content at time t relative to the initial exenatide content. The result is a ratio expressed as a percentage (%). The residual exenatide content corresponds to the percentage of exenatide protection.

[0125] [Tables5] Residual exenatide content in percentage (%) Conditions Mixture comprising simulated gastric medium (pH 1.2 with pepsin (3.2 mg / mL)) and buffered solution comprising 0.05 mg / mL of exenatide Mixture comprising simulated gastric medium (pH 1.2, with pepsin (3.2 mg / mL)) and buffered solution comprising 1 mg / mL of exenatide Mixture comprising simulated gastric medium (pH 1.2 without pepsin) and buffered solution comprising 0.05 mg / mL of exenatide T = Oh NA NA NA T = 1h 94.1% 98.6% - T = 2h 92.8% 97.8% 116%

[0126] [Tableauxô] Residual exenatide content in percentage (%) Conditions Mixture comprising simulated gastric medium (pH 1.2 without pepsin) and solution comprising exenatide (without buffer system) Mixture comprising simulated gastric medium (pH 1.2, with pepsin (3.2 mg / mL)) and solution comprising exenatide (without buffer system) T = Oh 100% 0% T = 2h 100% 0%

[0127] Results

[0128] The results are presented in Tables 5 and 6. Exenatide was protected by the system capable of buffering the pharmaceutical composition in the presence of pepsin. The composition according to the invention also made it possible to protect exenatide in the absence of pepsin (Table 5). However, when exenatide was introduced alone (without a buffer system) in a gastric environment with pepsin, exenatide was completely degraded (Table 6). These results show the protective effect of the buffer system on exenatide in gastric conditions and in the presence of pepsin.

[0129] Example 4: Measurement of the protection of semaglutide with a composition according to the invention compared to the Rybelsus® product, under gastric conditions reproduced in vitro (acid pH and addition of pepsin)

[0130] Gastro-resistance tests with semaglutide were conducted at a concentration of 0.05 mg / mL (5 mg of semaglutide in 100 mL final). The simulated gastric medium was prepared following the same protocol as described in Example 3.

[0131] The Rybelsus® product comprises semaglutide, sodium salcaprozate (SNAC), Povidone, microcrystalline cellulose, and magnesium stearate.

[0132] Step 1) A 14 mg Rybelsus® tablet was used for the comparative tests and was dissolved in 50 mL of drinking water for 3 minutes with stirring. The final semaglutide concentration was 0.28 mg / mL.

[0133] Step 2) An effervescent tablet (according to Example IA) was added or not to the solution obtained in step 1. After cessation of effervescence, 50 ml of 0.2 N HCL at pH 1.2 was added to obtain a final solution of 100 ml of 0.1 N HCL, which corresponds to the simulated gastric medium. The final concentration of semaglutide is 14 mg per 100 ml.

[0134] Step 3) Pepsin was then added or not to the solution obtained in step 2, at the conventional dose of 3.2 mg / mL. The test was carried out for 2 hours at a temperature of 37°C.

[0135] The semaglutide content was specifically measured by high-performance liquid chromatography (HPLC). The residual content was calculated by measuring the semaglutide content at time t relative to the initial semaglutide content. The result is a ratio expressed as a percentage (%). The residual semaglutide content corresponds to the percentage of protection of semaglutide.

[0136] [Tables?] Residual content of semaglutide in percentage (%) Mixture comprising simulated gastric medium (pH 1.2 with pepsin (3.2 mg / mL mg / mL)) and buffered solution comprising 0.05 mg / mL of semaglutide Mixture comprising simulated gastric medium (pH 1.2 without pepsin) and buffered solution comprising 0.05 mg / mL of semaglutide T = Oh NA NA T = 1h 104.6% 103.5% T = 2h 105.2% 104.1%

[0137] [Tables8] Residual content of semaglutide in percentage (%) Mixture comprising simulated gastric medium (pH 1.2 without pepsin) and solution comprising Rybelsus (without buffer system) Mixture comprising simulated gastric medium (pH 1.2 with pepsin) and solution comprising Rybelsus (without buffer system) Mixture comprising simulated gastric medium (pH 1.2, with pepsin), buffered solution and solution comprising Rybelsus T = Oh NA NA NA T = 1h 78.6% 0% 102.8% T = 2h 16.2% 0% 96.8%

[0138] Results

[0139] The results show total protection of semaglutide in gastric medium simulated in the presence of pepsin and with the buffer system (Table 7). In the absence of pepsin, semaglutide is also stable in the presence of the buffer system (Table 7). The results show that in the absence of pepsin, Rybelsus is only 78% stable for 1 h in gastric medium and is only maintained at 16% after 2 hours (Table 8). Semaglutide formulated in Rybelsus is completely and immediately degraded by pepsin in simulated gastric medium and without buffer system (Table 8). Thus, the pharmaceutical composition of the invention makes it possible to protect the Rybelsus product from acidity in gastric medium and from pepsin.

[0140] Sequence Listing SEQ ID NO: 1 Human GLP-1 HDEFERHAEGTFTSDVSSYLEGQAAKEFIA WLVKGRG SEQ ID NO: 2 Human GLP-1 (7-36) HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR SEQ ID NO: 3 Human GLP-1 (7-37) HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR G

Claims

Claims

1. A pharmaceutical composition for use as a medicament, in a form suitable for the oral treatment of a disease, said pharmaceutical composition comprising: (i) a proteinaceous active ingredient, said proteinaceous active ingredient being a Glucagon-like peptide-1 (GLP-1) receptor agonist, and (ii) a system capable of buffering the pharmaceutical composition at a pH ranging from 4 to 8, said pharmaceutical composition being free of any additional compound capable of protecting the proteinaceous active ingredient from degradation by digestive enzymes.

2. A pharmaceutical composition for use according to claim 1, wherein the GLP-1 receptor agonist is selected from GLP-1, a GLP-1 analog, exendin-4 or an exendin-4 analog.

3. A pharmaceutical composition for use according to any one of claims 1 or 2, wherein the disease is a metabolic disease, such as type 2 diabetes, non-alcoholic steatohepatitis and / or obesity.

4. A pharmaceutical composition for use according to any one of claims 1 to 3, wherein the GLP-1 receptor agonist is (a) GLP-1 or a GLP-1 analogue selected from liraglutide, dulaglutide, albiglutide and semaglutide, preferably semaglutide, or (b) exendin-4 or an exendin-4 analogue selected from exenatide and lixisenatide.

5. A pharmaceutical composition for use according to any one of claims 1 to 4, wherein the composition is in liquid form or in solid form.

6. A pharmaceutical composition for use according to any one of claims 1 to 5, wherein the system capable of buffering the pharmaceutical composition is selected from phosphate, acetate, maleate, phthalate, succinate, citrate, imidazole, tetrabutylammonium, trihydroxymethylaminomethane, tris-glycine, bicarbonate, barbitol, tris-EDTA BSA, copper sulfate and zwitterionic systems.

7. Pharmaceutical composition for use according to any one of claims 1 to 6, wherein the system capable of buffering the pharmaceutical composition makes it possible to obtain a pH ranging from 4.5 to 7.5, preferably ranging from 5 to 7, even more preferably from 6 to 7.

8. A pharmaceutical composition for use according to any one of claims 1 to 7, wherein the system capable of buffering the pharmaceutical composition is capable of protecting at least 70% of the protein active ingredient from degradation by at least one digestive enzyme when the pharmaceutical composition is brought into contact with said digestive enzyme(s), for example at least 75%, at least 80%, at least 85%, at least 90%, at least 95%.

9. A pharmaceutical composition for use according to claim 8, wherein the system capable of buffering the pharmaceutical composition is capable of protecting at least 70% of the protein active ingredient from degradation by pepsin when the pharmaceutical composition is contacted with 2 to 5 mg / ml of the pepsin for one hour.

10. A pharmaceutical composition for use according to any one of claims 1 to 9, wherein the composition does not comprise insulin, a derivative thereof or an analogue thereof and / or wherein the composition does not comprise any other protein active ingredient(s).

11. A pharmaceutical composition for use according to any one of claims 1 to 10, wherein the composition is a composition in solid form which comprises: (i) from 0.5 to 20% by mass of mono-sodium phosphate dihydrate relative to the total mass of the pharmaceutical composition, (ii) from 10 to 60% by mass of anhydrous mono-sodium citrate relative to the total mass of the pharmaceutical composition, (iii) from 20 to 95% by mass of sodium bicarbonate relative to the total mass of the system capable of buffering the pharmaceutical composition, (iv) from 0.5 to 20% by mass of sodium benzoate relative to the total mass of the pharmaceutical composition, and (v) from 0.0001 to 5% by mass of the GLP-1 receptor agonist, preferably semaglutide, relative to the total mass of the pharmaceutical composition, preferably from 0.001 to 1%, of preferably still from 0.01 to 0,5% by mass of the GLP-1 receptor agonist relative to the total mass of the pharmaceutical composition.,

12. A pharmaceutical composition for use according to any one of claims 1 to 6, characterized in that it is a ... of claims 1 to 11, wherein the composition is a composition in solid form which comprises: (i) 120 milligrams (mg) of monosodium phosphate dihydrate, (ii) 1142 mg of anhydrous monosodium citrate, (iii) 2076 mg of sodium bicarbonate, (iv) 157 mg of sodium benzoate, and (v) 0.5 to 40 mg of a GLP-1 agonist, preferably semaglutide.

13. A process for preparing a composition according to any one of claims 1 to 12, wherein a protein active ingredient is mixed with a system capable of buffering said pharmaceutical composition to a pH ranging from 4 to 8, said protein active ingredient is a Glucagon-like peptide-1 (GLP-1) receptor agonist.

14. A reagent kit for use as a medicament, in a form suitable for the oral treatment of a disease, said reagent kit comprising: (i) a pharmaceutical composition in solid form comprising a proteinaceous active ingredient, said proteinaceous active ingredient being a Glucagon-like peptide-1 (GLP-1) receptor agonist, and (ii) a pharmaceutical composition comprising a buffer system, wherein said pharmaceutical composition comprising a buffer system (ii) is capable of buffering the pharmaceutical composition comprising the proteinaceous active ingredient (i) at a pH ranging from 4 to 8, when compositions (i) and (ii) are mixed in solution, said reagent kit being free of any additional compound capable of protecting the proteinaceous active ingredient of the pharmaceutical composition (i) against degradation by digestive enzymes.